New Indication: Sotorasib in kRAS G12C Mutant Pancreatic Cancer
Study
| International, multicenter, open-label, phase 1–2 trial |
| Pretreated, locally advanced or metastatic pancreatic cancer with KRAS p.G12C mutation |
| Sotorasib (n=38) |
Efficacy
| ORR: 21% [10-37] |
| mDoR: 5.7 mos [1.6-NR] |
| mPFS: 4.0 mos [2.8 -5.6] |
| mOS: 6.9 mos [5.0-9.1] |
Safety
| Grade 3 AEs: diarrhea (5%) |
N Engl J Med 2023; 388:33-43
Sotorasib in KRAS p.G12C–Mutated Advanced Pancreatic Cancer
http://doi.org/10.1056/NEJMoa2208470
Reviewed by Elvin Chalabiyev, MD on Mar 15, 2023
